Clinical trial · Interventional
PECS-2 for Breast Surgery
Regional Anesthesia for Breast Cancer Surgery, Effects on Postoperative Wellbeing and Disease Recurrence.
NCT03117894CI-TRIAL-00052118completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There is no consensus regarding which alternative is the best anesthesia for breast surgery, general anesthesia and morphine for postoperative analgesia or a combination of regional anesthesia and general anesthesia that possibly attenuates or abolishes the need for morphine. The current study aims to determine which of the two strategies that is best in relation to postoperative pain, nausea and risk of recurrence of the disease.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anesthesia | — | UNRESOLVED | — |
| Anesthesia Morbidity | — | UNRESOLVED | — |
| Breast Neoplasm Female | — | UNRESOLVED | — |
| Regional Anesthesia | — | UNRESOLVED | — |
| Regional Anesthesia Morbidity | — | UNRESOLVED | — |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Arcoxia, 120 mg | Drug | — | UNRESOLVED |
| Betamethason 4 mg | Drug | — | UNRESOLVED |
| Morphine | Drug | — | UNRESOLVED |
| Ondansetron 4 mg | Drug | — | UNRESOLVED |
| Paracetamol 1,5 g | Drug | — | UNRESOLVED |
| Propofol | Drug | — | UNRESOLVED |
| Remifentanil 50 microg/ml | Drug | — | UNRESOLVED |
| Ropivacaine 5 mg/ml, 35 ml | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- GA with RA
- description
- Regional Anesthesia and General Anesthesia.
- interventionNames
- Drug: Ropivacaine 5 mg/ml, 35 ml
- Drug: Remifentanil 50 microg/ml
- Drug: Betamethason 4 mg
- Drug: Paracetamol 1,5 g
- Drug: Propofol
- Drug: Arcoxia, 120 mg
- Drug: Ondansetron 4 mg
- type
- ACTIVE_COMPARATOR
- label
- GA without RA
- description
- Only General Anesthesia (without a supplemental Regional Anesthesia).
- interventionNames
- Drug: Remifentanil 50 microg/ml
- Drug: Betamethason 4 mg
- Drug: Paracetamol 1,5 g
- Drug: Propofol
- Drug: Arcoxia, 120 mg
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Unilateral surgery on the breast because of suspected malign disease. Exclusion Criteria: Bilateral surgery Metastases other than in the axilla Body Mass Index (BMI) \> 35 Not able to communicate in Swedish Dementia American Society of Anesthesiology (ASA) 4 or 5 Chronic pain treatment (use of opiates or medicine for neuropathic pain \> 7 days the last month) Known allergy to Morphine or Ropivacaine Congestive Heart Failure, New York Heart Association (NYHA) IIIB or worse Chronic renal failure (S-creatinine increased) Immunosuppression (more than 10 mg daily of Prednisolone or stronger medication) No axillary exploration planned
References
Publications (1)
- DERIVEDAhlberg H, Wallgren D, Hultin M, Myrberg T, Johansson J. Less use of rescue morphine when a combined PSP/IPP-block is used for postoperative analgesia in breast cancer surgery: A randomised controlled trial. Eur J Anaesthesiol. 2023 Sep 1;40(9):636-642. doi: 10.1097/EJA.0000000000001795. Epub 2023 Jan 12. PMID 36633115